Copyright © 2021. Inderes Oyj. All rights reserved.

Organic sales growth:
Q1, 2022: 15% (7)

EBITDA margin:
Q1, 2022: 36% (34)

1 January-31 March 2022

  • Net sales increased by 21% to SEK 162 million (134).
  • Sales increased organically by 15% (7), currency effect 6 %.
  • EBITDA amounted to SEK 59 million (46).
  • EBITDA margin amounted to 36% (34).
  • Profit before tax amounted to SEK 49 million (36).
  • Earnings per share before and after dilution were SEK 1.61 (1.19).
  • Cash flow from operating activities amounted to SEK 38 million (26).

CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China and Japan. The company derives the majority of its revenue from the sale of analyzers.